Celeras Dx multiplexed antibody tests provide a quick and quantitative overview of a panel of biomarkers.
The point-of-care tests to monitor the inflammation and organ status of patients aim to support clinicians judging the inflammatory, organ and coagulation status of severely ill (especially septic) patients. Following the new sepsis definition, a range of different organ markers (kidney, nervous system, heart), coagulation and inflammation biomarkers are monitored in a single test.
The test is under clinical validation and currently for research use only.
next at the Investor Days Thueringen in Erfurt and here our elevator pitch (18 June, 2019).
Celeras Dx - Part of Cube Dx GmbH | Westbahnstrasse 55 | 4300 St. Valentin (Austria) | firstname.lastname@example.org